New imaging tracer may reveal Chemo's reach in pancreatic cancer
NCT ID NCT05141643
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 26 times
Summary
This early-phase study tests whether a special PET scan using an experimental tracer called 18F-FAC can show how much of the standard chemotherapy drug gemcitabine is taken up by pancreatic tumors. About 30 adults with pancreatic cancer will receive the tracer before starting treatment. The goal is to gather information that could help doctors predict which patients might benefit most from chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.